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Serial accumulation of mutations to fixation in the SLYNTVATL (SL9) immunodominant, 
HIV p17 Gag-derived, HLA A2-restricted cytotoxic T  lymphocyte epitope produce the 
SLFNTIAVL triple mutant “ultimate” escape variant. These mutations in solvent-exposed 
residues are believed to interfere with TCR recognition, although confirmation has 
awaited structural verification. Here, we solved a TCR co-complex structure with SL9 
and the triple escape mutant to determine the mechanism of immune escape in this 
eminent system. We show that, in contrast to prevailing hypotheses, the main TCR 
contact residue is 4N and the dominant mechanism of escape is not via lack of TCR 
engagement. Instead, mutation of solvent-exposed residues in the peptide destabilise 
the peptide–HLA and reduce peptide density at the cell surface. These results highlight 
the extraordinary lengths that HIV employs to evade detection by high-affinity TCRs with 
a broad peptide-binding footprint and necessitate re-evaluation of this exemplar model 
of HIV TCR escape.
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inTrODUcTiOn
CD8+ cytotoxic T  lymphocytes (CTLs) form a critical component in immune control of HIV 
infection. However, the virus has adopted numerous strategies to evade detection by these 
important immune cells (1, 2). Notably, the high rate and poor fidelity of replication produces 
a viral quasispecies to allow rapid selection of sequence variants that evade CTLs. This immune 
escape mutation is often associated with loss of viral fitness (3). The effects of immune escape 
from some HLA class I alleles, particularly HLAs B27 and B57 (3, 4), can be significant and delay 
progression to AIDS. There has been considerable work on immune escape from HIV epitopes 
presented by the most frequent HLA worldwide, HLA A2 (5). The majority of these studies 
have focussed on the immunodominant response through the p17 HIV Gag-derived epitope SL9 
(amino acids 77–85, sequence SLYNTVATL) (6–23). Responses to SL9 are uncommon in acute 
infection but are dominant during the long, asymptomatic, chronic infection period where over 
70% of HLA A2+ HIV-infected individuals mount a strong response to this epitope (13, 18, 19). 
Immune escape from SL9-specific CTL during this period has been studied extensively and is 
known to follow well-described patterns (6, 7). The leucine residues at positions 2 and 9 in SL9 
are located within an α-helix (21) and are critical for trimerisation of the P17 Gag protein (24). 
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Mutations within these residues are believed to produce highly 
compromised virus (11, 24). These residues also act as the 
principal anchors for securing SL9 into the HLA A2-binding 
groove (22) and ensure that the virus does not use the arche-
typical escape strategy of mutating primary MHC anchors to 
block epitope presentation at the infected cell surface (25–27). 
Instead, in the face of SL9-specific CTL pressure, HIV has been 
observed to undergo preferred mutation at positions 3, 6, and 
8 in the epitope (6, 7, 9). The dominant mutations seen at these 
positions (Y3F, V6I, and T8V) correlate with a lower viral load 
suggesting that they result in a loss of viral fitness, a notion 
that is supported by the rapid reversion to the wild-type SL9 
sequence in the absence of T-cell selection pressure (6, 7). The 
available evidence suggests that HIV balances the combined 
pressures of immune escape vs. viral fitness at the SL9 epitope 
by successive fixation of mutations at positions 3, 6, and 8 in the 
subtype A, B, and D SL9 SLYNTVATL consensus sequence over 
a >10-year period (6, 7). Indeed, McMichael and colleagues 
have described the triple mutant SLFNTIAVL sequence 
(3F6I8V; mutations in bold underlined text) as the “ultimate” 
escape mutant in SL9 (6).
Here we use structure and protein biophysics to deconstruct 
how HIV escapes from the well-studied (9–11) SL9-specific 
868 TCR. We add to the existing data by providing the first 
ever TCR–pMHC structures in this exemplar model of how 
HIV evades engagement by host TCRs. We find that the 868 
TCR interacts with HLA A2–SLYNTVATL (A2–peptide from 
here on in) with the expected binding topography but exhibits 
an unusual degree of structural rearrangement upon interac-
tion with A2–SLYNTVATL. The 868 TCR also contacts all 
five central residues in SL9 (positions 3–8) and binds with an 
unprecedentedly high affinity for a natural TCR. Surprisingly, 
4N is the major contact residue—not the 3Y, 6I, or 8T that 
mutate to precipitate immune escape. This enabled the genera-
tion of a high-resolution structure of the 868 TCR in complex 
with the SLFNTIAVL ultimate escape variant. These results 
challenge current thinking on the mechanism by which HIV 
escapes at SL9 and demonstrate the extraordinary tactics that 
the virus can employ to escape from CTL responses that can 
involve TCRs with a very broad footprint and a very high 
natural binding affinity.
MaTerials anD MeThODs
construct Design
The 868 TCR α and β chains, HLA A2 heavy chain, and β2m 
chain were generated by PCR mutagenesis and cloning. All 
sequences were confirmed by automated DNA sequencing (Lark 
Technologies). TCR expression constructs were designed with 
a disulphide linked construct to produce the soluble domains 
(variable and constant) for both the α (residues 1–207) and 
β chains (residues 1–247) (28, 29). The HLA A2 heavy chain 
(residues 1–248) (α1, α2, and α3 domains), tagged, or not tagged 
with a biotinylation sequence, and β2m (residues 1–100) were 
also cloned and used to make the pMHCI complexes. The TCR 
α and β chains, the HLA A2 α chain, and β2m sequences were 
inserted into separate pGMT7 expression plasmids under the 
control of the T7 promoter (30).
Protein expression, refolding,  
and Purification
Competent Rosetta DE3 E. coli cells were used to produce the 
TCR α and β chains, HLA A2 heavy chain, and β2m in the form 
of inclusion bodies using 0.5 mM IPTG to induce expression and 
protein were chemically refolded as described previously (31).
pMHCI Biotinylation
Biotinylated pMHCI was prepared as previously described (32).
surface Plasmon resonance (sPr) 
experiments
Surface plasmon resonance equilibrium binding analysis was 
performed using a BIAcore T100™ equipped with a CM5 sen-
sor chip as previously reported (32, 33). HLA DR1, generated 
as in Ref. (34), was used as a negative control on flow cell 1. SPR 
kinetic analyses were carried out to determine the KD values for 
the TCR, at 25°C. For all kinetic experiments, approximately 
300 RUs of pMHC was coupled to the CM5 sensor chip surface. 
The TCR was then injected at concentrations ranging from 10 
times above and 10 times below the known KD of the interac-
tion at 45 µl/min. The KD values were calculated assuming 1:1 
Langmuir binding [AB = B × ABMAX/(KD + B)], and the data 
were analysed using a global fit algorithm (BIAevaluation™ 
3.1). The kon, koff, and KD values were calculated by global fitting 
of the data using BIAevaluation™ 3.1 software. For the ther-
modynamics experiments we used the KD determined by SPR 
at different temperatures with the standard thermodynamic 
equation ΔG = RT ln KD and the standard non-linear van’t Hoff 
equation [ΔG° = ΔH°−  TΔS° + ΔCp°(T°−  T0)°− TΔCp° ln 
(T/T0)] with T0 = 298 K. For stability experiments, single injec-
tions of 50 µM 868 TCR over the SL9 variants were performed 
after different incubation times at 37°C, and the RU values were 
recorded.
isothermal Titration calorimetry (iTc)
Isothermal titration calorimetry experiments were performed 
using a Microcal VP-ITC (GE Healthcare) as previously described 
(35), with 30  µM pHLA-I in the calorimeter cell and 210  µM 
soluble 868 TCR in the syringe. Buffer conditions were 20 mM 
Hepes (pH 7.4) containing 150 mM NaCl and 20 injections of 
2  µl volume each were performed. Results were processed and 
integrated with the Origin 6.0™ software distributed with the 
instrument. ITC experiments were performed in duplicate.
adhesion Frequency assay
We used an adhesion frequency assay to measure the 2D affinity 
of TCR–pMHC interactions at the cell membrane as previously 
described (36). Briefly, human T-cells transfected with the 868 
TCR were mounted onto one micro-pipette and, on the other 
pipette, human red blood cells coated with pMHC by biotin–
streptavidin coupling served as both a surrogate APC and an 
adhesion sensor for detecting the TCR–pMHC interaction. Site 
3Cole et al. Unanticipated HIV Immune Escape Mechanism
Frontiers in Immunology | www.frontiersin.org November 2017 | Volume 8 | Article 1503
densities of TCR and pMHC were measured by flow cytometry 
as previously described (37). All assays were performed using 
at least 5 cell pairs, and calculated as an average of 100 cell–cell 
contacts.
crystallisation, Diffraction Data collection, 
and Model refinement
All protein crystals were grown at 18°C by vapour diffusion via 
the sitting drop technique. 200 nl of 1:1 molar ratio TCR and 
pMHCI (10 mg/ml) in crystallisation buffer (10 mM Tris pH 8.1 
and 10 mM NaCl) was added to 200 nl of reservoir solution. 868 
crystals were grown in TOPS (38) in 0.1 M sodium cacodylate 
pH 6.5, 20% PEG 8000, and 0.2  M ammonium sulphate (38). 
868-A2–SLYNTVATL crystals were grown in TOPS in 0.1  M 
sodium cacodylate pH 6.0, 15% PEG 4000 and 0.2 M ammonium 
sulphate (38). 868-A2–SLYNTIATL co-crystals were grown in 
TOPS in 0.1 M sodium cacodylate pH 6.0, 15% PEG 4000 and 
0.2 M ammonium sulphate (38). 868-A2–SLFNTIAVL crystals 
were grown in TOPS1 in 0.1 M sodium cacodylate pH 5.5, 15% 
PEG 4000 and 0.2 M ammonium sulphate (38). A2–SLYNTIATL 
crystals were grown in TOPS in 0.1 M sodium cacodylate pH 
6.0, 25% PEG 4000 and 0.2  M ammonium sulphate (38). 
A2–SLFNTIAVL crystals were grown in TOPS in 0.1 M sodium 
cacodylate pH 6.0, 25% PEG 4000 and 0.2  M ammonium 
sulphate (38). All crystals were soaked in 30% ethylene glycol 
before cryo-cooling. All crystallisation screens and optimisation 
experiments were completed using an Art-Robbins Phoenix 
dispensing robot (Alpha Biotech Ltd, UK). Data were collected 
at 100 K at the Diamond Light Source, Oxfordshire. All datasets 
were collected at a wavelength of ~0.98Å using an ADSC Q315 
CCD or PILATUS Pixel detectors. Reflection intensities were 
estimated with the XIA2 package (39) and the data were scaled, 
reduced and analysed with SCALA and the CCP4 package 
(40). Structures were solved with molecular replacement using 
PHASER (41). Sequences were adjusted with COOT (42) and 
the models refined with REFMAC5. Graphical representations 
were prepared with PYMOL (43). The reflection data and final 
model coordinates were deposited with the PDB database 
(868, PDB: 5NMD; 868-A2–SLYNTVATL, PDB: 5NME; 868-
A2–SLYNTIATL, PDB: 5NMF; 868-A2–SLFNTIAVL, PDB: 
5NMG; A2–SLYNTIATL, PDB: 5NMH; A2–SLFNTIAVL, PDB: 
5NMK).
Thermal stability cD analysis  
of hla a2 complexes
Thermal stability of HLA A2/β2m/peptide complexes was 
determined by circular dichroism spectroscopy following the 
change of ellipticities Θ at 218 nm using an Aviv 215 instrument 
(Aviv Biomedical Inc., Lakewood, NJ, USA). Proteins were dis-
solved in 137 mM NaCl, 3 mM KCl, 8 mM Na2HPO4, and 1 mM 
KH2PO4, pH 7.4, at concentrations of ~3  μM as determined 
spectroscopically using calculated extinction coefficients (44). 
Melting curves were recorded from 4°C up to a maximum tem-
perature when protein aggregation was observed using a heating 
rate of ~0.5°C/min. Melting curves were analysed assuming a 
two-state trimer-to-monomer transition from the native (N) 
to unfolded (U) conformation N3 ↔  3U with an equilibrium 
constant K =  [U]3/[N3] =  F/[3c2 (1 −  F)3], where F and c are 
the degree of folding and protein concentration, respectively. 
Data were fitted as described (45) using the non-linear least-
squares routine of Origin V7.5 (OriginLab, Northampton, MA, 
USA). Fitted parameters were the melting temperature Tm, van’t 
Hoff ’s enthalpy ΔHvH at the transition midpoint, and the slope 
and intercept of the native baseline assumed as a linear function 
of the temperature. As protein complexes aggregated at various 
degrees of unfolding, the ellipticity of the unfolded state was 
set as a constant of −4,500 deg cm2 dmol−1 (46).
generation of 868 Tcr Transgenic 
T-cells
868 TCR construct (codon-optimised for human expression) 
was cloned into the third-generation lentiviral expression 
vector pELNS (kindly provided by James R. Riley, University 
of Pennsylvania, PA, USA). pELNS vector was engineered to 
contain rat CD2 (rCD2) gene to be used as a marker of lenti-
viral transduction of target cells. 868 TCR-α and TCR-β, and 
rCD2 were separated by a pair of “self-cleaving” 2A sequences 
(11). Lentiviral particles were prepared by calcium phosphate 
transfection of packaging plasmids (pRSV-Rev, pMDLg/
pRRE, pMD2.G) together with 868-encoding pELNS into 
HEK293T  cells. Supernatant was harvested 48- and 72-h post 
transfection and was subsequently concentrated by ultracen-
trifugation. Primary CD8+ T-cells were obtained from healthy 
donor blood bags (Welsh Blood Service) by density gradient 
centrifugation and positive selection using CD8 MicroBeads 
(Miltenyi Biotec, Bergisch Gladbach, Germany). Isolated T-cells 
were stimulated overnight with Gibco human T-activator CD3/
CD28 Dynabeads (ThermoFisher Scientific, Waltham, MA, 
USA) at 3:1 bead to T-cell ratio, and transduced with concen-
trated lentiviral stock in presence of 5 µg/ml polybrene (Santa 
Cruz Biotechnology, Santa Cruz, CA, USA). After 72 h rCD2+ 
cells were enriched by magnetic bead selection to yield >95% 
purity. For tetramer staining experiments, CD8+ T-cells were 
used without magnetic enrichment to leave a non-transduced 
internal control cell population. Similar methodology was 
used to transduce TCRβ chain negative Jurkat cells to allow 
the examination of tetramer binding in the absence of the CD8 
glycoprotein.
Tissue culture
T2 cells were maintained as suspension cells in R10 (RPMI 1640 
media, 10% FBS, penicillin, streptomycin, and l-glutamine, all 
Life Technologies, Paisley, UK) and passaged weekly or when 
required. Post enrichment, primary CD8+ T-cells were routinely 
expanded with allogeneic feeder PBMCs and phytohaemaglut-
tinin (PHA) in T-cell media as previously described (47). 868 
TCR expression was checked prior to assay using anti-rCD2 
antibody and A2-SLYNTVATL tetramer, with the protein 
kinase inhibitor Dasatinib (48) (Axon Medchem, Reston, VA, 
USA), and unconjugated anti-PE antibody (PE001, BioLegend, 
London, UK) used to enhance tetramer staining, as previously 
described (47, 49).
Table 1 | Peptides used in this study.
Peptide sequence abbreviation hla-restriction Parent protein
SLYNTVATL SL9 HLA A*0201 HIV p17 Gag
SLFNTVATL 3F HLA A*0201 HIV p17 Gag
SLYNIVATL 6I HLA A*0201 HIV p17 Gag
SLYNTVAVL 8V HLA A*0201 HIV p17 Gag
SLFNIVAVL 3F6I8V HLA A*0201 HIV p17 Gag
GILGFVFTL A2-flu HLA A*0201 Influenza matrix
HPVGEADYFEY HLA B*3501 EBV EBNA-1
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T-cell activation assays
For peptide pulsing assays, T2 cells were incubated with peptide 
for 1 h in 0.5 ml of AIM-V serum free media (ThermoFisher 
Scientific) in 5 ml FACS tubes at 37°C and 5% CO2, followed by 
4 washes with 4 ml of RPMI 1640 media. In assays using primary 
CD4+ T-cells as targets, these cells were purified from PBMC 
using magnetic microbead separation (Miltenyi Biotech). 
Peptides were synthesised to >95% purity, stored as 20  mM 
DMSO stocks at −80°C and 1 mM RPMI dilutions made on the 
day of assay. DMSO controls were treated the same as peptide 
pulsed. Post pulsing, T2 cells or CD4+ T-cells were incubated 
in 4.5 ml of AIM-V media at 37°C and 5% CO2 for 3–24 h or 
used immediately (0 h), such that cells were ready at the same 
time. 868 TCR transduced and non-transduced T-cells (30,000) 
were rested overnight in R5 (as for R10 but with 5% fetal bovine 
serum) then co-incubated in 96 U-well plates with T2 or CD4+ 
T-cells (60,000) in the presence of GolgiStop and GolgiPlug 
according the manufacturers (BD Biosciences, Oxford, UK), and 
anti-CD107a PE Antibody (H483, BD Biosciences). Controls 
included T-cells alone and T-cells with unpulsed T2 cells (nega-
tive control) or PHA. After 3.5–5  h of incubation, cells were 
labelled with the violet LIVE/DEAD fixable dead cell stain Vivid, 
anti-CD8 APC (BW135/80; Miltenyi Biotech) and anti-CD19 
pacific-blue (T2 cells) (BioLegend), and rCD2 (CD4 assay) and 
anti-CD4 APC-Vio770 (M-T466, Miltenyi Biotech; CD4 assay) 
antibodies. Cells were then stained with anti-TNFα PE-Vio770 
antibody (CA2, Miltenyi Biotec) using a Cytofix/Cytoperm kit 
(BD Biosciences) according to manufacturer’s instructions. Flow 
cytometry was performed on a FACSCanto II (BD Biosciences) 
and data analysed with FlowJo software (TreeStar, Ashland, 
OR, USA). For peptide alanine scans, 868 TCR transduced 
T-cells were rested overnight in R5 then incubated with T2 cells 
(60,000) and peptides at specified concentrations for 18  h in 
96U-well plates in 100 µl of R5. Supernatants (50 µl) were used 
for MIP-1β ELISA (R&D Systems, Minneapolis, MN, Canada) 
and GraphPad Prism (GraphPad Software, Inc., La Jolla, CA, 
USA) used to fit non-linear regression curves and calculate EC50 
for each peptide.
T2 Peptide–hla-a2 stability assays
For conventional peptide-binding assays, T2 cells were pulsed 
for 22  h with 10−5  M peptide in 0.2  ml of AIM-V media 
(ThermoFisher Scientific) in 5 ml FACS tubes at 37°C and 5% 
CO2, washed then stained with anti-HLA-A2 antibody (BB7.2 
BioRad, Hercules, CA, USA) for 10 min at RT, washed with PBS, 
and fixed with 2% paraformaldehyde for 20 min on ice. Peptides 
were synthesised to >95% purity, stored as 20 mM DMSO stocks 
at −80°C, and 1 mM AIM-V dilutions made on the day of assay. 
DMSO controls were treated the same as peptide pulsed. For 
peptide on-rates, T2 cells were treated as before but for the 
durations specified in the results (1–3 h) then stained and fixed. 
For peptide off-rates, T2 cells were pulsed overnight, then a pro-
portion of them stained immediately, and fixed as above, with 
remaining cells being washed in an excess of media (two times 
using 4 ml) and incubated in 4.5 ml of AIM-V for the specified 
times (h) at 37°C and 5% CO2, to allow peptide to dissociate, 
then stained and fixed as before. Flow cytometry was performed 
on a FACSCanto II (BD Biosciences) and data analysed with 
FlowJo software (TreeStar).
Peptides Used in This study
This study made use of the HIV SL9 peptide and variants thereof. 
The sequences and origin of these peptides, and other control 
peptides utilised, are listed in Table 1.
resUlTs
868 Tcr binding to a2–slYnTVaTl 
involves extensive structural 
reorganisation
Previous studies have demonstrated that over 1.7% of CD8+ 
T-cells from HLA A2+ HIV-infected patient 868, stained with 
A2–SLYNTVATL tetramer (10). 75% of these tetramer+ cells 
expressed a TRBV5-6+ TCR and an identical TRBV5-6 β-chain 
was observed in 10/18 transcripts sequenced in this study (CDR3 
sequence CASSLSAVQNNEQF) (10). This same β-chain was 
later shown to be present in all A2–SLYNTVATL tetramer+ cells 
in a T-cell line grown from patient 868 in 1996 (9). TCR chain 
antibody staining showed that all of these A2–SLYNTVATL 
tetramer+ T-cells co-expressed a TRAV12-2 chain (11). Our 
previous study confirmed that CD8+ T-cells expressing this TCR 
were unable to control HIV virus in vitro (11). Nevertheless, we 
were able to use phage display to select an artificially enhanced 
version of the 868 TCR that could recognise the SLFNTIAVL 
ultimate escape variant; thereby engineering foresight into an 
immune receptor (11). The detection of common SL9 escape 
mutants on the surface of HIV-infected HLA A2+ cells by CD8+ 
T-cells expressing engineered, but not wild-type, 868 TCR rein-
forced earlier studies suggesting that these mutants are presented 
by HLA A2 and that escape from the wild-type epitope is medi-
ated by loss of TCR binding (so-called “TCR escape”) (6, 7, 11, 
18). To understand how positions 3, 6 and 8 in SL9 impinge on 
TCR binding, we solved the structure of the wild-type 868 TCR 
in complex with A2–SLYNTVATL to 2.9 Å resolution (Table 2). 
The 868 TCR bound to A2–SLYNTVATL with a conventional, 
centrally-located, diagonal orientation with the TCR α-chain 
positioned over the α2 helix of MHC class I and the TCR β-chain 
positioned over the α1 helix (Figure 1A). The TCR crossing angle 
of 51.6° lies within the normal range for human TCR–pMHC 
complexes (50), enabling positioning of the TCR CDR3 loops 
centrally over the peptide, and the CDR1 and CDR2 loops 
predominantly over the MHC helices (Figure 1B). To gain extra 
insight into the mechanism by which the 868 TCR adopted this 
Table 2 | Data collection and refinement statistics for unligated 868 TCR and complex structures.
868 Tcr 868-a2–slYnTVaTl 868-a2–slYnTiaTl 868-a2–slFnTiaVl a2–slYnTiaTl a2–slFnTiaVl
Data collection
Space group P 1 21 1 P 21 21 2 P 21 21 2 P 21 21 2 P 1 21 1 P 1 21 1
cell dimensions
a, b, c (Å) 87.5, 50.6, 114.3 211.1, 85.1, 113.2 207.6, 84.7, 112.1 209.36, 85.11, 113.15 56.1, 80.1, 57.6 55.84, 79.03, 58.37
α, β, γ (°) 90, 90.2, 90 90, 90, 90 90, 90, 90 90, 90, 90 90, 115.8, 90 90, 116.11, 90
Resolution (Å) 43.8–2.1 (2.13–2.07) 64.8–2.9 (3.01–2.94) 34.0–2.9 (2.96–2.89) 99.5–2.8 (2.82–2.75) 31.7–1.6 (1.59–1.55) 48.4–1.7 (1.70–1.66)
Beam line I24 I03 I03 I04-1 I03 I24
Beam time code 6232-9 4532-1 6232-1 6232-10 4532-1 3262-9
Rmerge (%) 5.0 (72.3) 12.5 (95.9) 15.1 (84.0) 11.7 (86.7) 6.6 (73.3) 7.4 (130.3)
I/σI 12.1 (2.3) 12.4 (2.1) 10.9 (2.9) 13.0 (2.5) 12.2 (2.4) 9.5 (2.1)
Completeness (%) 98.6 (99.6) 99.1 (99.8) 100 (100) 99.9 (100) 99.4 (97.7) 98.9 (99.8)
Redundancy 3.5 (3.8) 7.5 (7.1) 7.9 (8.2) 7.4 (7.6) 4.1 (4.0) 3.6 (3.7)
No. reflections 60,507 (4,492) 44,013 (3,213) 45,223 (3,284) 53,560 (3,895) 66,024 (4,752) 53,691 (4,000)
refinement
No Rfree reflections 3,051 2,212 2,223 2,717 3,346 2,724
Rwork/Rfree 18.9/22.3 19.4/28.9 18.8/27.5 19.2/27.0 14.4/19.4 17.5/20.8
r.m.s. deviations
Bond lengths (Å) 0.0189 0.015 0.012 0.017 0.025 0.017
Bond angles (°) 1.970 1.665 1.483 1.954 2.107 1.832
Mean B value (Å2) 57.0 69.0 53.7 31.2 16.8 24.3
Wilson B-fac (Å2) 40.7 72.2 60.3 58.9 17.2 22.5
ML estimated  
coordinate error (Å)
0.144 0.387 0.365 0.300 0.049 0.070
One crystal was used for solving each structure.
Figures in brackets refer to the highest resolution bin.
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binding mode, we also solved the structure of the unbound 868 
TCR (Table  2). Comparison with the 868-A2–SLYNTVATL 
complex structure showed that extensive structural reorganisa-
tion of the CDR3 loops was required to avoid clashes with the 
solvent-exposed residues in the SL9 peptide. This resulted in an 
induced fit, or conformational pre-equilibrium binding mode 
where the TCR exists in two conformations in the unbound 
state, with the CDR3α loop “moving” 6.9  Å and the CDR3β 
moving 3.2 Å between the bound and unbound TCR structures 
(Figure 1C).
Closer examination of the interface between the TCR and the 
pMHC showed that the CDR3 loops almost exclusively made 
contacts with the peptide, forming a pincer around the solvent-
exposed 4N and 5T residues in the peptide (Figures 2A,B). The 
TCR–peptide interaction included 10 hydrogen bonds and 52 
vdW contacts, mainly focussed on 4N. The CDR1 and CDR2 
loops primarily contacted the α helices of the MHC, including 
interactions with all three restriction triad residues (MHC 
residues 65R, 69A, and 155Q) as well as strong interactions 
with MHC residues 72Q and 154E (Figures  2C,D). Although 
most of the TCR–pMHC interactions were focussed on these 
2 peptide residues and 5 MHC residues, the 868 TCR bound 
with a broad footprint, making additional bonds with all but 
2 peptide residues (1S and 9L) and a further 14 MHC residues. 
In total, the 868 TCR made 20 hydrogen bonds, and 121 van der 
Waals (vdWs) contacts with A2–SLYNTVATL (Table 3), which 
is in the higher range compared to previously published viral 
TCR–pMHC complexes (35). In summary, the 868 TCR utilised 
an induced fit, or conformation selection, binding mode to form 
a pincer-like interaction around the central solvent-exposed 
portion of the peptide. Additional contacts with distal peptide 
residues enabled a relatively extensive and broad binding inter-
face between the TCR and pMHC.
Tcr structure with the Ultimate sl9 
escape Variant
The 868-A2–SLYNTVATL complex structure demonstrated that 
the dominant contacts with the SL9 peptide were with the 4N 
residue rather than with the 3Y, 6V, or 8T residues that result 
in immune escape when substituted to create the SLFNTIAVL 
ultimate escape variant (6, 7). Alanine scan mutation across the 
SL9 peptide backbone showed an almost complete loss of recog-
nition with the L2A and Y3A changes. Alanine substitution at 
positions 4, 5, and 6 had the next greatest effect whereas peptides 
substituted at positions 1, 8, and 9 exhibited recognition equiva-
lent to the wild-type peptide (Figure 2E). In order to gain insight 
as to how natural escape mutations impinge on TCR binding, we 
also solved the structure of the 868 TCR with the SLYNTIATL 
variant present in the patient at the time the blood sample was 
used to grow the 868T-cell clone (9), and the SLFNTIAVL ulti-
mate escape variant (Table 2). Comparison of these structures 
with the 868 TCR in complex with the A2–SLYNTVATL index 
sequence showed that the 868 TCR engaged all the antigens in 
FigUre 1 | Structural analysis of the 868-A2–SL9-binding mode. (a) The overall binding mode of the 868 TCR (red and magenta cartoon) interacting with  
HLA A2 (grey surface) and the SLYNTVATL peptide (red sticks and surface). (b) Surface representation of the A2–SLYNTVATL complex looking down at the peptide. 
Positions of the 868 TCR CDR loops (1α—red, 2α—green, 3α—blue, 1β—yellow, 2β—cyan, 3β—orange) and the crossing angle of the TCR with the MHC groove  
is shown. (c) The positions of the 868 TCR CDR3 loops differ considerably between the ligated (red cartoon) and unligated (grey cartoon) structures.
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a similar conformation and with a similar interaction network 
(Figures 3A–E). We were initially surprised at being able to solve 
the structure of the 868 TCR in complex with the SLFNTIAVL 
peptide as this triple mutant is known to escape from CD8+ 
T-cells (6, 7). Indeed, this mutation is not well recognised by 
T-cells bearing the 868 TCR (9, 11). The failure of CD8+ T-cells to 
recognise the SLFNTIAVL mutation has previously been attrib-
uted to reduced interactions with the TCR (6, 7, 18, 23). Earlier 
structural analyses of A2–SLYNTVATL and A2–SLFNTIAVL 
have concluded that all three substitutions directly affected 
TCR recognition (6, 7). However, we observed only minor dif-
ferences at the TCR–peptide interface with these two ligands. 
For example, the 868 TCR made 3 hydrogen bonds and 12 vdWs 
with peptide residues 3Y, 6V, and 8T in the SLYNTVATL peptide 
compared to 2 hydrogen bonds and 15 vdWs contacts with 3F, 
6I, and 8V in the SLFNTIAVL peptide (Figures 3C,E). The total 
number of contacts in each complex (868-A2–SLYNTVATL: 141, 
868-A2–SLFNTIAVL: 146) was also similar, demonstrating that 
the 868 TCR could tolerate mutations at residues 3, 6, and 8 in 
SL9 (Table 3). Thus, because our structural data were inconsist-
ent with the hypothesis that SLFNTIAVL primarily affects TCR 
binding, and because sum contact numbers do not necessarily 
represent the accurate binding energy between two molecules, 
we undertook further structural and biophysical experimenta-
tion to determine the mechanism that results in poor T-cell 
recognition of SLFNTIAVL.
a2–slYnTVaTl Does not alter 
conformation When bound to 868 Tcr
Previous studies comparing SLYNTVATL and the SLFNTVATL 
mut ated peptide showed that they adopted different con for mations 
within the HLA A2 binding groove (7, 22). The T-cell recognition 
and on-rate kinetics with the G10 SL9-specific TCR in this study 
were very similar with A2–SLYNTVATL and A2–SLFNTVATL, 
leading the authors to conclude that one conformation, 
FigUre 2 | The 868 TCR focuses on residues 4N and 5T in the peptide. Hydrogen bonds show as red dotted lines, van der Waal’s contacts shown as black dotted 
lines in panels (a–D). (a) The 868 TCR (CDR3α in blue, CDR1α red and CDR3β orange sticks) binding to the solvent-exposed peptide residues 4N and 5T in the 
peptide (red sticks). (b) The 868 TCR (CDR3α in blue, CDR1α red sticks and surface) forms a tight pocket around peptide residue 4N (red sticks) during binding. 
(c,D) The restriction triad residues 72Q, 69A, and 155Q (grey sticks) play a central role in 868 TCR–MHC-mediated interactions (TCR CDR3α residues shown in 
blue, CDR2β in cyan, and CDR1α in green sticks). (e) 868 TCR transduced CD8+ T-cells from two HLA A2+ donors were co-incubated with T2 cells and alanine-
substituted peptides of SLYNTVATL (alanine already at position 7) overnight and supernatants used for MIP-1β ELISA. Non-linear regression curves and pEC50 for 
each peptide are displayed.
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common to both peptides, was recognised by TCRs (22) and 
suggesting that TCR interactions with either A2–SLYNTVATL or 
A2–SLFNTVATL required an induced fit in the pMHC. Thus, 
SL9-derived peptides may bind to MHC dynamically and undergo 
conformational changes during TCR docking. Conformational 
peptide changes would likely elicit an entropic penalty during 
TCR ligation, not revealed by differences in contacts, and could 
contribute to weaker binding. However, based on previously 
solved structures [A2–SLYNTVATL (22), A2–SLFNTVATL (22), 
A2–SLANTVATL (21), A2–SLYNTIATL (21), A2–SLYLTVATL 
(21), A2–SLYNVVATL (21), A2–ALYNTAAAL (21), and A2– 
SLFNTIAVL (21)], some of which we replicated in this study, 
we show that A2–SLYNTVATL, A2–SLYNTIATL, and A2–
SLFNTIAVL all adopt a similar structure to every unbound SL9 
peptide variant, apart from A2–SLFNTVATL (22), when ligated 
to the 868 TCR (Figure 4). These data make it possible to be more 
definitive about the direction of travel of the previously suggested 
induced fit model (22) (i.e., the odd one out is A2–SLFNTVATL 
and this peptide presumably adopts the more conventional struc-
ture for A2–SLYNTVATL type ligands prior to, or at the time 
Table 3 | Summary of co-complex structures of 868-A2–SLYNTVATL, 868-A2–
SLYNTIATL, and 868-A2–SLFNTIAVL.
868-a2–
slYnTVaTl
868-a2–
slYnTiaTl
868-a2–
slFnTiaVl
H-bonds (≤3.4 Å) 20 20 18
vdWs (≤4 Å) 121 118 128
Total contacts 141 138 146
CDR1/CDR2/CDR3 contacts (≤4 Å)
α Chain 13/33/41 9/23/46 8/22/47
β Chain 0/17/37 0/27/43 0/24/45
Peptide contacts 62 56 63
MHC contacts 79 82 83
Crossing angle (°) 51.6 50.3 51.7
Buried surface area (Å2) 2,396.2 2,469 2,698
Surface complementarity
TCR–MHC 0.50 0.51 0.55
TCR–peptide 0.72 0.70 0.71
TCR–pMHC 0.56 0.55 0.59
HB, hydrogen bond; SB, salt bridge; WB, water bridge; vdWs, van der Waals 
interactions.
A 3.4 Å cut-off was used for HBs, SBs, and WBs, and a 4 Å cut-off was used  
for vdWs.
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of, TCR binding). Furthermore, these data do not support the 
notion that HIV escape is mediated by dynamic differences in 
ligand engagement during TCR binding to SL9 variants.
The 868 Tcr adopts a similar  
energetic strategy during binding  
to sl9 escape Variants
We next explored the evidence for HIV escape being 
mediated by distinct TCR-binding parameters. It has been 
previously shown that the G10 SL9-specific TCR binds with 
a similar affinity to both A2–SLYNTVATL (KD  =  2.2  µM) 
and A2–SLFNTVATL (KD  =  5.2  µM) by SPR (22). Another 
study demonstrated that half maximal pMHC tetramer 
binding (DR50) to the SL9-specific D3 TCR was near identical 
for A2–SLYNTVATL, A2–SLFNTVATL, A2–SLYNTVAVL, 
A2–SLFNTVAVL, and A2–SLFNTIAVL (21). Finally, we 
have previously shown that the 868 TCR binds to a range 
of SL9 variants (11) (A2–SLYNTVATL, A2–SLYNTIATL, 
A2–SLYNTIAVL, A2–SLYNTVAVL, A2–SLFNTIATL, A2– 
SLFNTVAVL, A2–SLFNTVATL and A2–SLFNTIAVL). Con-
sequently, the available data show that SL9-specific TCRs can 
engage SL9 variants within an affinity range that would be 
expected to easily activate T-cells. Here, we reproduced SPR-
binding assays with the 868 TCR for the three ligands included 
in this study. These data demonstrated that the 868 TCR 
bound to A2–SLYNTVATL with a KD of 82 nM (Figure 5A) con-
firming that this is, by far, the strongest binding natural TCR– 
peptide–MHC interaction ever recorded (51, 52). Indeed, the 
affinity was even greater with the A2–SLYNTIATL variant 
(KD = 38 nM; Figure 5B) that dominated in the patient at the time 
the blood sample was taken that was used to generate the 868 
T-cell line (9, 10). 868 TCR interactions with A2–SLYNTVATL 
and the A2–SLYNTIATL variant were characterised by a rela-
tively slow off-rate (koff = 1.6 × 10−2–7.3 × 10−3 s−1) compared to 
the majority of other natural TCR–pMHC interactions (average 
koff  ~  2  ×  10−1  s−1) (51). Although the strength of the 868- 
A2–SLFNTIAVL interaction was 21-fold and 45-fold weaker 
than for A2–SLYNTVATL or A2–SLYNTIATL, respectively, 
due to a much faster off-rate (koff = 2.1 × 10−1 s−1), the affinity 
(KD of 1.77  µM; Figure  5C) was still in the range of the very 
best natural anti-pathogen TCRs (52, 53). Thus, this weaker 
affinity alone was unlikely to explain the ability of the 
SLFNTIAVL variant to evade T-cell detection. Indeed, we 
have described a functional HLA A2-restricted TCR that binds 
its cognate pMHC with over 100-fold weaker affinity than 
the 868 TCR and A2–SLFNTIAVL (54, 55). To get a more 
complete picture of how the 868 TCR engages its cognate 
ligands we also undertook thermodynamic analyses by SPR 
(Figures 5D–F; Table 4) and directly by isothermal calorimetry 
(ITC; Figures  5G–I). The results of these independent tech-
niques correlated well and showed that 868 TCR engagement 
was driven by energetically favourable enthalpy and entropy 
changes to all three ligands. Thus, for the 868 TCR, there was 
a net increase in the number of electrostatic interactions and 
a transition from order-disorder during binding. Considering 
that the 868 TCR CDR3 loops underwent similarly large 
conformational changes during engagement to all three SL9 
variants studied here (shown for 868-A2–SLY interaction in 
Figure  1C), a movement that would probably be entropically 
unfavourable, the expulsion of ordered water molecules from 
the interface, and/or order–disorder transitions in other parts 
of the molecules presumably contributed to the net favourable 
entropic change of the interaction. The lower affinity of 868 
TCR for A2–SLFNTIAVL compared to A2–SLYNTVATL or 
A2–SLYNTIATL was associated with a much reduced enthalpic 
component, but more favourable entropy. We used 2D binding 
analysis to confirm our observations using SPR (Figures 5J,K). 
In accordance with our previous findings with other TCRs 
(55, 56), we observed an identical relationship between the 
strength of interaction between 868 and the three SL9-derived 
ligands by 2D analysis and SPR. 868-A2–SLYNTIATL was char-
acterised by the strongest 2D effective affinity (1.6 × 10−3 μm4), 
followed by 868-A2–SLYNTVATL (1.0 × 10−3 μm4), with 868-
A2–SLFNTIAVL generating the weakest effective 2D affinity 
(5.9 × 10−4 μm4). To further confirm our observations from 2D 
and 3D binding experiments, we next examined the binding of 
pMHC tetramers to the 868 TCR at the T-cell surface. Staining 
of 868 TCR-transduced CD8+ primary T-cells was similar for 
tetramers made with A2–SLYNTVATL, A2–SLYNTIATL, and 
A2–SLFNTIAVL (Figure  6A). The CD8 coreceptor is known 
to bind to a site on MHC class I distinct from the TCR docking 
platform and cooperates with the TCR to aid the engagement 
of pMHC tetramers (57) and the absence of CD8 binding is 
known to raise the TCR affinity threshold required for tetramer 
staining (58, 59). 868 TCR+ Jurkat T-cells, that do not express CD8, 
also stained equally well with A2–SLYNTVATL, A2–SLYNTIATL, 
and A2–SLFNTIAVL tetramers (Figure 6B). Given our obser-
vations that the TCR affinity threshold required for T-cell 
activation is considerably lower than that required for pMHC 
tetramer binding (58) and finding that these reagents can even fail 
to stain fully functional T-cells (47, 60), our results suggest that 
the SLFNTIAVL ultimate escape variant would still be a very 
FigUre 3 | The 868 TCR uses a virtually identical conformation when interacting with the common escape mutants SLYNTiATL and SLFNTiAVL. (a) Identical 
overall binding mode of 868 TCR interacting with A2–SLYNTVATL (red), A2–SLYNTiATL (orange), and A2–SLFNTiAVL (green). HLA A2 in grey cartoon. (b) Surface 
representation of the A2–SLYNTVATL complex looking down at the peptide. Positions of the 868 TCR CDR loops in the A2–SLYNTVATL (red), A2–SLYNTiATL 
(orange), and A2–SLFNTiAVL (green) complexes. Crossing angle of the TCR is indicated. (c) Contacts between the 868 TCR and residues 3Y, 6V, and 8T in the 
SLYNTVATL peptide that constitute the positions that a commonly mutated by HIV. (D) Contacts between the 868 TCR and residues 3Y, 6I, and 8T in the 
SLYNTiATL peptide. Although slightly different, the total number of contacts between the 868 TCR and A2–SLYNTiATL is similar to the 868-A2–SLYNTVATL 
complex. (e) Contacts between the 868 TCR and residues 3F, 6I, and 8V in the A2–SLFNTiAVL triple escape mutant peptide. Again, the total number of contacts 
between the 868 TCR and A2–SLFNTiAVL is similar to the complex with the wild-type index peptide. Hydrogen bonds shown as red dotted lines and van der 
Waal’s contacts shown as black dotted lines in panels (c–e).
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efficient T-cell agonist. Indeed, the 868 TCR-transduced primary 
CD8+ T-cells exhibited similar reactivity to SLYNTVATL and 
SLFNTIAVL peptides when using standard T-cell activation 
assay whereby T-cells, antigen-presenting cells, and peptide are 
added directly to tissue culture wells and allowed to incubate 
(Figure  6C). We conclude that while there is a substantial 
FigUre 4 | 868 TCR binding alters the peptide conformation of the A2–SLYNTVATL escape mutants. Structural comparison of the A2–SLYNTVATL escape variants 
unligated and in complex with the 868 TCR. (a,b) A2–SLYNTVATL in complex with the 868 TCR (red sticks) vs. unligated A2–SLYNTVATL (cyan sticks). Small 
changes in the positions of the side chains that occur during TCR binding are circled. (c,D) A2–SLYNTiATL (orange sticks) in complex with the 868 TCR vs. 
unligated A2–SLYNTiATL (yellow sticks). Small changes in the positions of the side chains that occur during TCR binding are circled. (e,F) A2–SLFNTiAVL  
(green sticks) in complex with the 868 TCR vs. unligated A2–SLFNTiAVL (purple sticks). Small changes in the positions of the side chains that occur  
during TCR binding are circled.
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reduction of TCR binding to the SLFNTIAVL triple mutant 
sequence, this reduction cannot explain the observed immune 
escape per se as assumed by all previous studies in this system 
(6, 7, 11, 23).
The other way by which peptides can escape from host CTL 
surveillance is by mutating MHC anchors to reduce binding 
and presentation at the infected cell surface. However, previous 
studies have shown that the SLFNTIAVL peptide binds to HLA 
A2 with 50–400% of the affinity the index SL9 sequence depend-
ing on the study (Table 5). Such minor relative differences were 
not thought to be able to explain how the triple mutant peptide 
escapes from CTL (6, 7, 9, 18). Our own studies with a modified 
version of the 868 TCR that recognises the escape variants well 
showed that this TCR could recognise CD4+ T-cells infected 
with primary HIV isolates carrying known escape variants 
(11). Thus, these variants must be presented at the cell surface 
in the context of HLA A2. Importantly, these variants were 
not recognised by T-cells expressing the wild-type 868 TCR, 
thus verifying that these viruses are indeed escape mutants 
(11). Consequently, the established literature indicates that the 
common variant peptides in this system bind sufficiently well to 
HLA A2 to be presented (6, 7, 9, 18) and sufficiently well to the 
868 and D3 TCRs to be recognised by T-cells expressing these 
SL9-specific receptors. These apparently incongruous findings 
prompted us to next re-examine peptide binding in the SL9 
system.
cTl escape by the Ultimate sl9  
escape Variant Mediated by a Fast 
Peptide Off-rate
Detailed analysis of the thermal melting of A2–SLYNTVATL, 
A2–SLYNTIATL, and A2–SLFNTIAVL by circular dichroism 
showed the melting temperature (Tm) of the wild-type peptide 
was higher than that of the triple mutant (57°C compared to 
49°C; Figures  7A,B) suggesting that the triple mutant is less 
stable. These data are in accordance with two previous studies 
showing that SLFNTIAVL binds to HLA A2 with ~50% reduced 
affinity compared to SL9 (9, 18) but at odds with two studies 
indicating that SLFNTIAVL is the better ligand (6, 7). Peptide 
binding to HLA A2 has not previously been thought to result 
in the immune escape observed with this epitope, which instead 
has been attributed to a lack of recognition by SL9-specific TCRs 
(6, 7, 11, 23). Stabilisation of HLA A2 at the T2 cell surface in 
FigUre 5 | Continued
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the continuous presence of 100 µM peptide (steady-state binding; 
Figure 7C) showed that the SLFNTIAVL peptide stabilised HLA 
A2 with 89% of that seen with the wild-type SL9 peptide after 
3  h. This relatively minor difference increased in an overnight 
assay where stabilisation with SLFNTIAVL was ~65% of that 
seen with the wild-type peptide. Our previous examinations of 
HLA A2 peptide stability by SPR have shown that good agonists 
produce pMHC with a half-life of >6 h in a cell free system (61). 
Similar experiments, performed by examining the relative bind-
ing of 868 TCR to A2–peptide by SPR over a time course at 37°C, 
showed that both A2–SLYNTVATL and A2–SLYNTIATL had a 
half-life of >7 h. By contrast, the half-life of A2–SLFNTIAVL on 
the same chip was <2 h (Figure 8A). We thus reasoned that the 
stabilisation of peptide–HLA measured in a short-term binding 
assay like those previously used in this system (9, 18) would be 
determined more by peptide on-rate than the peptide off-rate 
or dwell time. To further test this possibility, we examined the 
“on rate” of peptide in T2 cell stabilisation assays. Relative stabi-
lisation was similar for the SLYNTVATL, SLFNTIAVL and the 
GILGFVFTL influenza matrix-derived peptide that is often used 
as a positive control for HLA A2 binding (Figure 8B: left panel). 
We also examined the stability of these A2–peptide complexes at 
the cell surface by monitoring the amount of HLA A2 on T2 cells 
incubated with each peptide prior to washing and further culture. 
Table 4 | Affinity and kinetic measurements of 868-A2–SLYNTVATL, 868-A2–
SLYNTIATL, and 868-A2–SLFNTIAVL at different temperatures.
Mhc–peptide Temp (°c) kon (M−1s−1) koff (s−1) kD
Kinj 
(μM)
kDequi 
(μM)
A2–SLYNTVATL 5 1.1 × 104 2.2 × 10−3 0.2 0.23
8 2.8 × 104 3.7 × 10−3 0.13 0.11
18 7.1 × 104 7.1 × 10−3 0.1 0.072
25 1.5 × 105 1.6 × 10−2 0.11 0.082
32 4.3 × 105 5.6 × 10−2 0.13 0.124
37 4.0 × 105 6.9 × 10−2 0.17 0.21
A2–SLYNTiATL 5 9.2 × 103 1.3 × 10−3 0.13 0.16
8 5.4 × 104 2.7 × 10−3 0.05 0.048
18 7.6 × 104 4.2 × 10−3 0.055 0.035
25 1.4 × 105 7.3 × 10−3 0.052 0.038
32 3.1 × 105 1.9 × 10−2 0.06 0.049
37 6.4 × 105 3.2 × 10−2 0.05 0.11
A2–SLFNTiAVL 5 2.3 × 104 7.7 × 10−2 3.3 2.2
8 6.3 × 104 1.1 × 10−1 1.7 1.7
18 1.3 × 105 1.8 × 10−1 1.42 1.65
25 1.4 × 105 2.1 × 10−1 1.48 1.77
32 1.6 × 105 3.0 × 10−1 1.9 2.11
37 1.0 × 106 5.3 × 10−1 0.53 2.3
FigUre 5 | Binding affinity and thermodynamic analysis of the 868 TCR binding to A2–SLYNTVATL, A2–SLYNTiATL, and a2–SLFNTiAVL. (a–c) Binding and 
kinetic analysis of the 868 TCR interaction with (a) A2–SLYNTVATL, (b) A2–SLYNTiATL, and (c) A2–SLFNTiAVL. Experiments were performed independently 
using a BIAcore T100 equipped with a CM5 sensor chip and repeated in triplicate on different days using different protein preparations. Representative data are 
shown. (D–F) Thermodynamic analysis of 868 TCR with the aforementioned ligands and surface plasmon resonance (SPR) as above. Thermodynamic parameters 
were calculated according to the Gibbs–Helmholtz equation (ΔG° = ΔH − TΔS°). The binding free energies, ΔG° (ΔG° = RTlnKD), were plotted against 
temperature (K) using non-linear regression to fit the three-parameter Van’t Hoff equation [RT ln KD = ΔH − TΔS° + ΔCp°(T − T0) − TΔCp° ln (T/T0) with 
T0 = 298 K]. (g–i) Thermodynamic analysis of the 868 TCR–pMHC interaction was also performed using isothermal titration calorimetry 200 instrument to directly 
measure ΔH. These analyses show consistent values to those generated by SPR. Overall, the 868 TCR uses a generally similar binding mechanism and 
thermodynamic signature to interact with all three ligands. (J) Effective 2D binding frequency, using at least 5 cell pairs, and calculated as an average of 100 
cell–cell contacts. (K) Effective 2D affinity (AcKa) calculated using adhesion frequency assays and reported in the text as geometric mean. Statistics were 
performed on log-transformed affinities and analysed with two-tailed, unpaired parametric t-tests and assumption of equal SDs.
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The vast majority of HLA A2 stabilised with GILGFVFTL or 
SLYNTVATL peptide was still present at the cell surface 3 h after 
the peptide was removed from the assay by cell washing. In stark 
contrast, most of the HLA A2 stabilised by the SLFNTIAVL 
peptide had decayed in half this time (Figure 8B: right panel). 
Collectively, these binding data explain how previous studies, 
using short-term binding assays in the continuous presence of 
peptide, have shown minor differences in the binding of SL9 and 
SLFNTIAVL escape variant (Table 5). They also suggest that the 
dominant mechanism by which the SLFNTIAVL mutant allows 
immune escape is due to this peptide producing a much shorter- 
lived peptide–HLA complex. This reduced half-life of antigen 
at the infected cell surface would be expected to considerably 
reduce the antigen density on infected cells and thereby facilitate 
immune escape. To test this notion, we next examined how long 
peptide pulsed cells could remain as T-cell targets for CD8+ 
T-cells transduced with the wild-type 868 TCR. These reveal-
ing experiments allowed examination of the combined effects 
of differences in TCR binding and HLA stability in a relevant 
biological context. Cells pulsed with the SLYNTVATL remained 
effective targets for 868 TCR-expressing CD8+ T-cells after 24 h 
of culture (Figure 8C; Figure S1 in Supplementary Material). By 
contrast, targets pulsed with the SLFNTVATL, SLYNTIATL, or 
SLYNTVAVL variant peptides showed reduced levels of recogni-
tion after 24 h. The SLFNTIAVL triple mutant sequence produced 
the largest effect and was recognised well if experiments were 
performed immediately but recognition dropped to less than 20% 
of that seen for the SLYNTVATL peptide at t0, after targets were 
cultured for 24 h prior to the T-cell recognition assay. Similar data 
were observed when primary CD4+ T-cells, which form the major 
reservoir for HIV virus in vivo, were used as targets (Figure 8D). 
Relative to SLYNTVATL, the SLFNTIAVL pulsed cells made 
FigUre 6 | 868 TCR-expressing T-cells bind escape mutant tetramers efficiently without the need for CD8. (a) Primary CD8+ T-cells were co-transduced with the 
868 TCR and rat (r)CD2 prior to staining with 0.5 µg (with respect to MHC) of irrelevant (A2–ALWGPDPAAA), A2–SLYNTVATL, A2–SLYNTiATL, and A2–SLFNTiAVL 
PE-conjugated peptide–MHC tetramers. Cells are gated on rCD2+CD8+ cells. Histograms show staining with indicated PE-conjugated tetramer with the mean 
fluorescence intensity (MFI) of this population displayed. (b) As for panel (a), but 868 TCR and rat (r)CD2 were transduced into TCRβ chain negative Jurkat cells. 
MFI of tetramer staining is shown for cells in the rCD2+ tet+ gate. (c) 868 TCR transduced were incubated with T2 cells and either SLYNTVATL or SLFNTiAVL 
peptide at the concentrations shown for 5 h followed by the detection of CD107a and TNFα by flow cytometry.
Table 5 | Relative binding of SLYNTVATL and SLFNTIAVL to HLA A*0201.
slYnTVaTl slFnTiaVl Method
100% 48% S35 methionine pulse chase (9)
100% (KD = 50 nM) 53% (KD = 94 nM) Direct competition with  
radio-labelled ligand (18)
100% (KD = 300 nM) 300% (KD = 100 nM) Quantitative HLA A2 ELISA (6)
100% (KD ~ 3.5 nM) 400% (KD ~ 0.8 nM) Quantitative HLA A2 ELISA (7)
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better targets at t0 (125%) but their ability to activate the 868 TCR 
cells diminished to 18% when allowed to culture for 24 h prior to 
assay (Figure 8D; Figure S2 in Supplementary Material). These 
results suggest that the major mechanism by which SLFNTIAVL 
escapes from CTL is through loss of peptide–HLA stability, 
although reduced TCR interaction with this mutant is also likely 
to play a secondary role.
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FigUre 7 | Stability of A2–SLYNTVATL, a2–SLYNTiATL, and a2–SLFNTiAVL. (a) CD thermal denaturation curves recorded at 218 nm are shown for selected 
samples as indicated. Dots represent measured values fitted assuming a two-state trimer-to-monomer transition (solid lines) as described in Section “Materials and 
Methods.” (b) Bar graphs of the thermal stability with respect to melting temperature (upper) and van’t Hoff’s enthalpy of unfolding (lower panel). Error bars in panels 
(a,b) represent SD resulting from the multivariable curve fitting of data from one experiment with each peptide. (c) T2 cells incubated for 3 or 22 h with 10−5 M of 
each peptide [Influenza (Flu) Matrix, GILGFVFTL, HIV Gag wild-type SLYNTVATL, and Gag triple mutant SLFNTiAVL] or DMSO control were stained for HLA-A2 and 
fixed. The dashed line is set at the mean fluorescence intensity (MFI) of the negative control peptide (EBV HPVGEADYFEY that binds HLA B*3501).
FigUre 8 | Instability at the cell surface mediates viral escape by the triple mutant epitope, A2–SLFNTiAVL. (a) Relative binding of 868 TCR to A2–peptide 
complexes by SPR over time. The SPR chip was maintained at 37°C. Functional half-life was determined by injecting the 868 TCR at a fixed concentration of 
100 µM over 720 min and recording the drop in total RUs over 8 different time points. A faster drop in RUs (converted into a T1/2) was interpreted to indicate greater 
peptide instability, detected by loss of binding by the antigen-specific 868 TCR. (b) Left panel shows relative HLA-A2 expression following incubation (0, 3, and 
22 h) of T2 cells with indicated peptide. Results are normalised to the maximum mean fluorescence intensity seen for each peptide. The right panel shows T2 cells 
incubated with peptide for 22 h prior to being washed and cultured in an excess of AIM-V media for the indicated times prior to staining and fixing. Data displayed 
as HLA-A2 expression relative to maximum seen at 22 h. (c) T2 cells were pulsed for 1 h with the peptides shown, washed extensively, and then cultured in an 
excess of media for 3 h (black bar) or 24 h (open bar) before being co-incubated for 5 h with T-cells from two donors transduced with the 868 TCR. CD107a and 
TNFα were used to establish percentage reactivity by flow cytometry. Values were normalised relative to SLYNTVATL peptide. SEM is shown for two different donor 
T-cells. Untransduced CD8+ T-cells did not respond to peptide (data not shown). Raw data for panel (c) is shown in Figure S1 in Supplementary Material.  
(D) As panel (c) but using primary HLA-A2− and HLA-A2+ CD4+ T-cells as targets and culturing in excess media for either 0 or 24 h prior to assay. Raw data for 
panel (D) is shown in Figure S2 in Supplementary Material.
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DiscUssiOn
Recognition and escape from the HLA A2-restricted HIV 
epitope SL9 has been examined in well over 50 studies to date, 
but major questions are still outstanding in this system as there 
has been no TCR–A2–SL9 co-complex structure. Here, we solved 
the structure of the free 868 TCR, a TCR first described almost 
20  years ago (10), and the structure of this TCR in complex 
with A2–SLYNTVATL. Comparison of the free and ligated TCR 
structures suggested an “induced fit” mechanism that involved 
major structural reorganisation of the antigen binding face of the 
TCR. The CDR3 loops made the biggest movement (almost 7 Å 
for CDR3α and >3  Å for CDR3β) to avoid steric clashes with 
the central portion of the peptide, while the CDR1 and CDR2 
loops interacted mainly with MHC via a more “lock-and-key” 
interaction.
It has been known for over a decade that that the SLYNTVATL 
and SLFNTVATL bind to HLA A2 with very different confor-
mations, but engage the G10 TCR with near identical on-rates, 
leading the authors to conclude that one conformation, com-
mon to both peptides, was recognised by TCRs (22). Since 
A2–SLYNTVATL does not change upon TCR binding, we 
can now be confident that the conformation adopted by this, 
and many other SL9 variants (21), dominates during TCR 
recognition. Thus, the evidence suggests that A2–SLFNTVATL 
undergoes an induced fit upon TCR binding (22) although 
conclusive proof will await a TCR-A2–SLFNTVATL structure. 
We further solved the co-complex structure of the 868 TCR with 
the A2–SLYNTIATL (the variant that predominated in patient 
868 in 1996 when the patient blood sample from which this 
T-cell clone was grown was taken), and the structure of the 868 
TCR in complex with the A2–SLFNTIAVL, the ultimate escape 
variant in this system. Resolution of the latter structure came as 
a surprise as residues that mutate in positions 3, 6, and 8 to pro-
duce this mutant are known to be solvent exposed and had been 
assumed to act as prominent TCR contacts (6, 7, 21–23). In con-
trast to this prevailing hypothesis we found that the asparagine 
at position 4 was the dominant contact residue. Indeed, there 
were more contacts with this residue than with the position 3 
tyrosine, position 6 valine, and position 8 threonine combined. 
An alanine mutation scan across the peptide backbone showed 
that while positions 4 and 5 in SLYNTVATL were important 
for recognition, the most severe non-MHC anchor change was 
Y3A. In accordance, the position 3Y sub-library also gave the 
strongest response of the 180 sub-libraries during a 9-mer posi-
tional scanning combinatorial library screen of T-cells trans-
duced with the 868 TCR (62). The importance of the tyrosine 
residue at position 3 is consistent with our previous observation 
that large bulky amino acids at this position in HLA A2-bound 
peptides can form a bridge with more C-terminal residues (usu-
ally position 5) (63). Replacing residue 3 with a smaller alanine 
side chain can abolish this important intra-peptide stabilisation 
and have knock-on effects at peptide residue 4 that abrogate 
TCR binding. Thus, our findings here point towards a com-
mon mechanism of peptide presentation by HLA A2 in which 
peptide residue 3 can be essential for maintaining antigenic 
identity.
We next undertook a detailed biophysical and thermody-
namic study of 868 TCR binding to A2–SLYNTVATL, A2–
SLYNTIATL, and A2–SLFNTIAVL. The 868 TCR exhibited, 
by far, the strongest affinity of a peptide–HLA ligand for a 
natural TCR (52) and bound to A2–SLYNTVATL and A2–
SLYNTIATL ligands with KDs of 82 and 38 nM, respectively, or 
over 10× stronger binding than the next highest TCR–pMHC 
interaction measured by BIAcore (52). The median affinity for 
human antiviral TCR–pMHC interactions is KD ~5 μM (52). 
868 TCR binding was characterised by a relatively slow off-
rate from the A2–SLYNTVATL and A2–SLYNTIATL ligands. 
The other SL9-TCR that has been examined by SPR, G10, had 
an off-rate 3.75 times faster than 868, and a 4.5 times slower 
on rate, resulting in a weaker affinity of KD of 2.2  µM for 
A2–SLYNTVATL compared to 868 (22). While binding of the 
868 TCR was much reduced for A2–SLFNTIAVL compared 
to the other ligands, it still had a very respectable affinity 
(KD = 1.77 μM) that falls at the higher end of the spectrum for 
TCR agonists (52).
The mode of 868 TCR engagement and its affinity with the 
A2–SLFNTIAVL ultimate escape variant in this system did not 
lend full support to the prevailing belief that loss of recogni-
tion of SL9 occurs mainly via interfering with TCR binding. 
The fact that CD8+ T-cells transduced with the 868 TCR could 
recognise SLFNTIAVL pulsed target cells well and stained with 
A2–SLFNTIAVL tetramers was also a surprise, but in accordance 
with an earlier study that showed that A2–SLFNTIAVL bound to 
the D3 TCR as well as A2–SLYNTVATL in tetrameric form and 
that the SLFNTIAVL concentration required for half maximal 
lysis was a highly respectable 4 × 10−10 M (21). In further accord-
ance with positions 3, 6, and 8 not dominating A2–SL9-specific 
TCR binding, the position 4 asparagine sub-library was by far the 
most potent of the 180 sub-mixtures for activating T-cell clone 
003 known to express a different SL9-specific TCR (62). These 
combined data do not support the notion that the SLFNTIAVL 
escapes from CTL via lack of TCR binding, prompting us to take 
a closer look at the MHC binding of ligands in this system. Data 
from three different studies using three different methodologies 
show that SLFNTIAVL binds to HLA A2 with 50–400% of the 
affinity of SLYNTVATL. Our previous SPR experiments have 
shown that good agonists produce pMHC with a half-life of >6 h 
in a cell-free system (61). Indeed, our data here show that both 
A2–SLYNTVATL and A2–SLYNTIATL had half-lives of over 
7 h on an SPR chip maintained at 37°C compared to <2 h for 
A2–SLFNTIAVL. We reasoned that the peptide-binding assays 
that have been performed previously in this system, including by 
ourselves (9), would be most influenced by peptide on-rate but 
that the biology would be most linked to peptide off-rate at the 
target cell surface. HLA A2+ target cells pulsed with SLYNTVATL 
peptide remained effective targets for SL9-specific CD8+ T-cells 
after 24 h of culture as has been observed with a different HIV 
Gag-derived epitope (27). The SLFNTVATL, SLYNTIATL and 
SLYNTVAVL peptides [which bind to the 868 TCR with dissocia-
tion constants of 2.9 µM, <100 nM, and ~300 nM, respectively 
(52)] were seen well when targets presenting these ligands were 
used immediately for T-cell assays but exhibited only 67, 60, and 
35% recognition of that observed with SLYNTVATL peptide 
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